2 Reasons to Avoid Valeant Pharmaceuticals Intl Inc, and 1 Stock to Buy Instead

Valeant Pharmaceuticals Intl Inc (TSX:VRX)(NYSE:VRX) is a great Canadian success story. But there are better options for your portfolio.

| More on:
The Motley Fool

In Canada, few companies are able to seriously compete on the global stage. But Valeant Pharmaceuticals Intl Inc (TSX: VRX)(NYSE: VRX) is one of them, and has become one of the country’s big success stories. Investors have been handsomely rewarded along the way, with the stock increasing by nearly 800% over the past five years.

But there are still some very big reasons for avoiding Valeant, and two are listed below. Then we take a look at a stock you should buy instead.

1. Earnings quality

Before looking at this issue, it is important to understand Valeant’s strategy. Instead of spending heavily on research and development, the company prefers to buy product lines and companies. Then Valeant will squeeze costs out of its new franchise. It’s a formula that’s worked very well since CEO Michael Pearson took over.

But that creates some accounting issues. For one, it makes Valeant’s margins appear better than they are, by shifting R&D expenses off the income statement — instead the company incurs these costs through the price paid for acquisitions. Secondly, the company reports various earnings figures (such as cash earnings per share) that don’t factor in various acquisition-related costs.

This has started to draw some attention from Wall Street. While activist investor Bill Ackman is willing to defend Valeant, other smart people are not. Included in this mix is Jim Chanos, who became famous for betting against Enron before its bankruptcy. These short sellers often refer to Valeant as a “roll-up,” meaning a company that simply uses an inflated stock price to become a serial acquirer. If they are right, then the music will stop eventually, and the result will not be pretty.

2. Price

There’s no denying that Valeant shares have rocketed up to astronomical levels. To illustrate, the company reported cash earnings per share of $6.24 (and actual earnings per share of $-2.70). But the stock still trades at about $130, despite all the negative headlines. Clearly, there’s plenty of room for the shares to fall.

1 stock you should buy instead: Brookfield Asset Management

Alternative investment manager Brookfield Asset Management Inc (TSX: BAM.A)(NYSE: BAM) also has its fair share of accounting issues. Even the Securities and Exchange Commission has gotten involved, and Brookfield has had to change the way it reports results. Investing in the company is very much like riding in a race car with a blindfold.

But Brookfield has a much longer-term track record than Valeant, with a 19% annual return to shareholders from 1994 to 2013. Over a time period that long, it’s clear that Brookfield’s success is nothing temporary; rather, it shows just how adept the company is at making sound investments.

Brookfield does have one thing in common with Valeant: a proven ability to make a mark on the world stage. More importantly, Brookfield’s business model has much less uncertainty surrounding it. So the company’s shares are more worthy of a spot in your portfolio.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

engineer at wind farm
Dividend Stocks

Making Your $20,000 Investment Work Harder for the Long Term

Building wealth doesn’t have to be complicated when you invest in strong, top dividend-paying stocks like these.

Read more »

Two senior friends playing beat tennis on sand tennis court
Retirement

The $6,000 Investment Strategy That Could Transform Your Retirement

Is your investment strategy keeping up with the changing retirement needs? If not, its time to upgrade your strategy.

Read more »

Investor wonders if it's safe to buy stocks now
Energy Stocks

Where Will Enbridge Be in 3 Years?

Enbridge stock is rapidly expanding its gas pipeline business and the next three years will define its position in the…

Read more »

View of high rise corporate buildings in the financial district of Toronto, Canada
Dividend Stocks

4 Incredibly Cheap Real Estate Stocks to Buy Now

These four REITs are some of the best in Canada and all trade cheaply, making them some of the best…

Read more »

investor looks at volatility chart
Stocks for Beginners

How to Invest $10,000 in Today’s Uncertain Market for Future Gains

Staying invested through volatility can pay off, especially with TSX-listed stocks that offer strength and attractive long-term upside.

Read more »

hand stacking money coins
Stocks for Beginners

An Easy 5-Stock Portfolio for New Investors

Want to establish an easy 5-stock portfolio? Both new and seasoned investors alike should consider these five gems.

Read more »

stocks climbing green bull market
Stocks for Beginners

2 TSX Stocks Taking Off to Watch in the Second Half of 2025

These two stocks are some of the best out there not just for growth, but for stability.

Read more »

chart reflected in eyeglass lenses
Energy Stocks

1 Energy Stock up 28% to Buy Right Now

CNQ stock is bouncing back from a big slump. Are more gains on the way?

Read more »